Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Simulations Plus (SLP – Research Report) today. The company’s shares closed last Thursday at $41.15.
Hewitt covers the Healthcare sector, focusing on stocks such as Codexis, Avid Bioservices, and Inotiv. According to TipRanks, Hewitt has an average return of 2.7% and a 46.91% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Simulations Plus with a $55.00 average price target.
The company has a one-year high of $52.51 and a one-year low of $32.64. Currently, Simulations Plus has an average volume of 98.03K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Simulations Plus (SLP) Company Description:
Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.
Read More on SLP:
- Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
- Simulations Plus (SLP) Q2 Earnings Cheat Sheet
- FDA awards Simulations Plus a grant through proposal with University of Bath
- Simulations Plus management to meet with Oppenheimer
- Simulations Plus extends pact with Translational Toxicology Division at NIEHS
